Drug intelligence / Profile preview

PF-06667272

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-06667272 is a small molecule myeloperoxidase (MPO) inhibitor that was developed by Pfizer for the treatment of non-alcoholic steatohepatitis (NASH). The drug acts as a peroxidase inhibitor, targeting MPO, an enzyme implicated in inflammatory processes and liver injury. It was classified as a novel molecular entity and reached Phase 1 clinical trials to assess safety, tolerability, and pharmacokinetics in healthy volunteers. Development for NASH was discontinued after Phase 1[1][2][3].

Targets

MPO (Myeloperoxidase)

Beyond the preview

Go deeper on PF-06667272.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06667272.

Explore the full profile